Review on fungal enzyme inhibitors - potential drug targets to manage human fungal infections

被引:17
|
作者
Ramakrishnan, Jayapradha [1 ]
Rathore, Sudarshan Singh [1 ]
Raman, Thiagarajan [1 ]
机构
[1] SASTRA Univ, Sch Chem & Biotechnol, CRID, Thanjavur 613401, Tamil Nadu, India
来源
RSC ADVANCES | 2016年 / 6卷 / 48期
关键词
CANDIDA SPECIES MECHANISMS; YEAST-CELL WALL; CARBONIC-ANHYDRASE; ANTIFUNGAL ACTIVITY; AMPHOTERICIN-B; ECHINOCANDIN RESISTANCE; INVASIVE ASPERGILLOSIS; GLUCOSAMINE-6-PHOSPHATE SYNTHASE; REDUCED SUSCEPTIBILITY; COMBINATION THERAPY;
D O I
10.1039/c6ra01577h
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Invasive fungal infections caused by opportunistic fungal pathogens have been emerging as a global problem of great concern as they are associated with increased morbidity and mortality. Despite this, there are very limited drugs of choice to treat fungal infections. The continuous usage of these drugs is associated with resistance development and thus this is another area of concern. Fungal enzymes represent one of the most important and potential targets for drug development, as they are essential for their growth and establishment in the host. In this review, we have discussed the well established and currently available enzyme inhibitors as therapeutic choices to treat fungal infections as well as those enzyme inhibitors that have been identified as suitable drug candidates to manage fungal infections. Thus, the study of fungal biosynthetic enzymes and their inhibitors could potentially show a promising way of drug development for emerging and re-emerging fungal infections of humans.
引用
收藏
页码:42387 / 42401
页数:15
相关论文
共 50 条
  • [31] Human immunodeficiency virus and fungal infections
    Guarner, Jeannette
    SEMINARS IN DIAGNOSTIC PATHOLOGY, 2017, 34 (04) : 325 - 331
  • [32] Hidden Killers: Human Fungal Infections
    Brown, Gordon D.
    Denning, David W.
    Gow, Neil A. R.
    Levitz, Stuart M.
    Netea, Mihai G.
    White, Theodore C.
    SCIENCE TRANSLATIONAL MEDICINE, 2012, 4 (165)
  • [33] Recent drug development and treatments for fungal infections
    Madhura Roy
    Sonali Karhana
    Md Shamsuzzaman
    Mohd. Ashif Khan
    Brazilian Journal of Microbiology, 2023, 54 : 1695 - 1716
  • [34] Recent drug development and treatments for fungal infections
    Roy, Madhura
    Karhana, Sonali
    Shamsuzzaman, Md
    Khan, Mohd. Ashif
    BRAZILIAN JOURNAL OF MICROBIOLOGY, 2023, 54 (03) : 1695 - 1716
  • [35] FUNGAL-INFECTIONS IN DRUG-USERS
    LEEN, CLS
    BRETTLE, RP
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 : 83 - 96
  • [36] Drug-Resistant Fungal Infections on the Rise
    Davidson, Robert
    US PHARMACIST, 2024, 49 (04)
  • [37] Drug Repurposing for the Treatment of Bacterial and Fungal Infections
    Miro-Canturri, Andrea
    Ayerbe-Algaba, Rafael
    Smani, Younes
    FRONTIERS IN MICROBIOLOGY, 2019, 10
  • [38] Comparative genomics allowed the identification of drug targets against human fungal pathogens
    Abadio, Ana Karina R.
    Kioshima, Erika S.
    Teixeira, Marcus M.
    Martins, Natalia F.
    Maigret, Bernard
    Felipe, Maria Sueli S.
    BMC GENOMICS, 2011, 12
  • [39] Comparative genomics allowed the identification of drug targets against human fungal pathogens
    Ana Karina R Abadio
    Erika S Kioshima
    Marcus M Teixeira
    Natalia F Martins
    Bernard Maigret
    Maria Sueli S Felipe
    BMC Genomics, 12
  • [40] Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review
    Elewa, Hazem
    El-Mekaty, Eman
    El-Bardissy, Ahmed
    Ensom, Mary H. H.
    Wilby, Kyle John
    CLINICAL PHARMACOKINETICS, 2015, 54 (12) : 1223 - 1235